Financial reports
10-Q
2024 Q1
Quarterly report
14 Mar 24
10-K
2023 FY
Annual report
29 Jan 24
10-Q
2023 Q3
Quarterly report
28 Aug 23
10-Q
2023 Q2
Quarterly report
13 Jun 23
10-Q
2023 Q1
Quarterly report
14 Mar 23
10-K
2022 FY
Annual report
30 Jan 23
10-K
2015 FY
Annual report
22 Sep 16
10-Q
2015 Q3
Quarterly report
30 Mar 16
10-Q
2015 Q2
Quarterly report
22 Jan 16
10-Q
2015 Q1
Quarterly report
24 Mar 15
Current reports
8-K
Entry into a Material Definitive Agreement
17 Apr 24
8-K
Vitro Biopharma Announces New Chief Financial Officer
22 Jan 24
8-K
Entry into a Material Definitive Agreement
12 Jan 24
8-K
Entry into a Material Definitive Agreement
22 Nov 23
8-K
Entry into a Material Definitive Agreement
19 Jul 23
8-K
Material Modifications to Rights of Security Holders
7 Jul 23
8-K
Entry into a Material Definitive Agreement
16 Jun 23
8-K
Entry into a Material Definitive Agreement
8 Jun 23
8-K/A
Entry into a Material Definitive Agreement
12 May 23
8-K/A
Entry into a Material Definitive Agreement
12 May 23
Registration and prospectus
S-1/A
IPO registration (amended)
2 Feb 24
S-1/A
IPO registration (amended)
12 Dec 23
D
$3.00 mm in debt / options, sold $2.00 mm, 1 investor
1 Dec 23
S-1/A
IPO registration (amended)
28 Aug 23
8-A12B
Registration of securities on exchange
1 Aug 23
S-1/A
IPO registration (amended)
17 Jul 23
S-1/A
IPO registration (amended)
29 Jun 23
S-1/A
IPO registration (amended)
2 Jun 23
S-1/A
IPO registration (amended)
8 May 23
D/A
$2.50 mm in debt / options / securities to be acquired, sold $992.60 k, 9 investors
5 Apr 23
Proxies